Neurotech International (ASX:NTI) Debt-to-Equity : 0.00 (As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is Neurotech International Debt-to-Equity?

Neurotech International's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was A$0.00 Mil. Neurotech International's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was A$0.00 Mil. Neurotech International's Total Stockholders Equity for the quarter that ended in Dec. 2023 was A$4.80 Mil. Neurotech International's debt to equity for the quarter that ended in Dec. 2023 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Neurotech International's Debt-to-Equity or its related term are showing as below:

During the past 7 years, the highest Debt-to-Equity Ratio of Neurotech International was 0.42. The lowest was -0.94. And the median was 0.01.

ASX:NTI's Debt-to-Equity is not ranked ^*
in the Medical Devices & Instruments industry.
Industry Median: 0.22
* Ranked among companies with meaningful Debt-to-Equity only.

Neurotech International Debt-to-Equity Historical Data

The historical data trend for Neurotech International's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neurotech International Debt-to-Equity Chart

Neurotech International Annual Data

Trend

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Debt-to-Equity

Get a 7-Day Free Trial

0.42

-0.08

Neurotech International Semi-Annual Data
	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial										0.01	-	-	-	-

Competitive Comparison of Neurotech International's Debt-to-Equity

For the Medical Devices subindustry, Neurotech International's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Neurotech International's Debt-to-Equity Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Neurotech International's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Neurotech International's Debt-to-Equity falls into.

Neurotech International Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Neurotech International's Debt to Equity Ratio for the fiscal year that ended in Jun. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	3.962
	=	0.00

Neurotech International's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	4.795
	=	0.00

Neurotech International (ASX:NTI) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Neurotech International Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Neurotech International's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Neurotech International (ASX:NTI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Neurotech International Ltd (ASX:NTI) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

145 Stirling Highway, Suite 5 CPC, Nedlands, WA, AUS, 6009

Website

https://www.neurotechinternational.com

Neurotech International Ltd is a medical device and solutions company. It researches, designs, markets, and produces wearable neurotechnology devices to assist with neurological conditions such as autism. Geographically, all the business activities of the firm function through the region of Australia. It operates in one segment named Medical Device Development and Distribution.

Neurotech International (ASX:NTI) Headlines

From GuruFocus

13 Stocks With Dividend Yields Over 10%

By Dividend Dividend • 11-12-2014

By Dividend Dividend • 06-25-2013

How to Capitalize on the Bakken Oil Boom

By Vitaliy Katsenelson Vitaliy Katsenelson • 11-09-2013

9 Stocks With Yields Over 10% And Buy Or Better Rating

By Dividend Dividend • 08-17-2013

18 Stocks with Very High Yields (More Than 10%) and Earnings Growth

By Dividend Dividend • 12-20-2012

9 Stocks with Double-Digit Yields and Buy or Better Recommendations

By Dividend Dividend • 07-17-2013

20 Stocks with Yields over 10% and Highest Buy Ratings

By Dividend Dividend • 01-17-2013